日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Transforming Growth Factor-β-Activated Kinase 1 (TAK1) Alleviates Inflammatory Joint Pain in Osteoarthritis and Gouty Arthritis Preclinical Models.

转化生长因子-β激活激酶1(TAK1)可缓解骨关节炎和痛风性关节炎临床前模型中的炎症性关节疼痛

Freeze Robert, Hughes Philip, Haystead Timothy, Scarneo Scott

Investigation of SARS-CoV-2 individual proteins reveals the in vitro and in vivo immunogenicity of membrane protein.

对 SARS-CoV-2 单个蛋白质的研究揭示了膜蛋白的体外和体内免疫原性

Haystead Timothy, Lee Eric, Cho Kirstin, Gullickson Gail, Hughes Philip, Krafsur Greta, Freeze Robert, Scarneo Scott

Delineation of the distinct inflammatory signaling roles of TAK1 and JAK1/3 in the CIA model of rheumatoid arthritis

在类风湿性关节炎的CIA模型中,阐明TAK1和JAK1/3在炎症信号传导中的不同作用

Freeze, Robert; Yang, Kelly W; Haystead, Timothy; Hughes, Philip; Scarneo, Scott

Development and Efficacy of an Orally Bioavailable Selective TAK1 Inhibitor for the Treatment of Inflammatory Arthritis.

开发和评估口服生物利用度高的选择性TAK1抑制剂治疗炎症性关节炎的疗效

Scarneo Scott, Hughes Philip, Freeze Robert, Yang Kelly, Totzke Juliane, Haystead Timothy

A highly selective inhibitor of interleukin-1 receptor-associated kinases 1/4 (IRAK-1/4) delineates the distinct signaling roles of IRAK-1/4 and the TAK1 kinase.

白细胞介素-1受体相关激酶1/4(IRAK-1/4)的高选择性抑制剂阐明了IRAK-1/4和TAK1激酶不同的信号传导作用

Scarneo Scott A, Hughes Philip F, Yang Kelly W, Carlson David A, Gurbani Deepak, Westover Kenneth D, Haystead Timothy A J

TAK1: a potent tumour necrosis factor inhibitor for the treatment of inflammatory diseases

TAK1:一种强效的肿瘤坏死因子抑制剂,用于治疗炎症性疾病

Totzke, Juliane; Scarneo, Scott A; Yang, Kelly W; Haystead, Timothy A J